Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Data on cancer vaccines described by researchers at King's College London, King's College London School of Medicine
April 22nd, 2009
Investigators publish new data in the report 'Anti-tumor immunity in a model of acute myeloid leukemia.' "Whole-cell vaccines allow the induction of anti-tumor immune responses without the need to define tumor antigens," scientists in London, the United Kingdom report. "We wished to directly compare, for the first time, the capacity of B7-1, B7-2 and 4-1BB ligand (4-1BBL) costimulatory molecules to convert murine and human acute myeloid leukemia (AML) cells into whole vaccines. 32Dc-kit is a murine myeloid cell line, which develops an AML-like disease over a protracted period, emulating human AML disease development. 32Dc-kit cells were modified to express elevated...
Source: Vaccine Weekly (2009-04-22)
|
